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ABSTRACT: Micro-RNA signatures have emerged as advantageous biomarkers for disease prediction opening the route for the 
development of more direct and accurate therapies. There is an urgent need for reliable tools which can offer a fast, highly sensitive 
and selective detection of multiple miRNAs in complex matrices as opposed to the conventional techniques. Here, we demonstrate 
a nanophotonic biosensor with potential multiplexing capabilities based on interferometric bimodal nanowaveguides (BiMW) for 
ultra-sensitive detection of microRNAs in complex media. Concretely, the BiMW biosensor has been employed for the detection 
and quantification of miR-181a at attomolar concentrations (LOD = 23 aM) directly, and for the first time, in human urine samples 
of bladder cancer patients with no need for prior sample purification or amplification steps. We demonstrate the extremely selectivi-
ty of our methodology for miR-181a detection showing the discrimination of homologous sequences at single nucleotide mismatch 
and its pre-miRNA. A significant overexpression of miR-181a in bladder cancer patients was appreciated when compared with 
healthy controls, suggesting the implication of this miRNA in bladder cancer. Our results show that the BiMW biosensor can be 
used as an ultrasensitive and specific diagnostic tools by the early and fast detection and quantification of microRNAs for the pre-
diction of diseases (as cancer) with well-defined microRNA signatures. 
Mature microRNAs (miRNAs) are small and single-stranded 
non-coding RNAs typically containing ~19-23 nucleotides.1 
These short, endogenously expressed molecules are evolution-
ally conserved and they are present in a broad range of ani-
mals, plants, and viruses.2 They play important roles in modu-
lating several biological functions. Even though the under-
standing of their complex roles is not fully characterized, 
expression levels of specific miRNAs in tissues have already 
been correlated with cell fate decisions and outcome of serious 
disorders.3  
The establishment of miRNA-pattern panels with diagnosis 
value is gaining more and more interest. It can provide de-
tailed information of the presence of specific miRNAs which 
can determine the type of cancer and its stage of development 
(early or late stage, metastasis…). Genome-wide profiling has 
shown that miRNA expression signatures (miRNome) allow to 
discriminate with a high grade of accuracy different types of 
cancer4 and to identify the tissue of origin of poorly differenti-
ated tumors.5 miRNAs are more stable than long mRNAs due 
to their small size, permitting expression profiling from fixed 
tissues or other biological material like blood (whole blood, 
plasma or serum),6 circulating exosomes,7 urine,8 saliva9 or 
even sputum.10 This supports their possible use as novel, min-
imally invasive and robust biomarkers. Their profiling has 
shown to reflect the patterns observed in tumor tissues, sug-
gesting their use as easily detectable tumor biomarkers for 
early diagnosis.11 Moreover, miRNAs can be used in gene 
therapy for reestablishing genetic disorders.12, 13 
Efficient and reliable detection strategies are of urgent need 
toward understanding the functions of miRNAs in regulatory 
pathways. They can bring on the development of extremely 
accurate diagnostic tools and miRNA-based therapies at mo-
lecular level.14 Using miRNAs as analytical indicators holds 
many advantages over the traditional protein biomarkers since 
there are far fewer miRNAs species as compared to proteins.15 
Northern blot and reverse-transcription real-time polymerase 
chain reaction (RT-qPCR) techniques are considered the 
benchmark methods for miRNA detection.16, 17 Several novel 
miRNAs have been identified by Northern blotting analyses.17 
However, this method has a poor sensitivity requiring large 
amounts of sample input and is relatively time-consuming. On 
the other hand, although RT-qPCR can cover a broad dynamic 
range of miRNA concentrations with a relatively high sensitiv-
ity, it requires highly purified samples. The lack of standard-
ized protocols for miRNA extraction can introduce a high 
variability, leading to inaccurate analyses. In addition to these 
methods, microarray technology has been applied to the paral-
lel detection of multiple miRNAs.18 However, the complexity 
of miRNA labeling and narrow dynamic range of miRNA 
microarrays together with the difficulties for standardization 
limit their routine use in centralized laboratories. Next genera-
tion sequencing technology (NGS) has emerged as the pre-
ferred platform for studying miRNA expression since it allows 
to pool and sequence multiple samples in one lane of a se-
quencer.19 However, it can be influenced by sequencing errors 
and often requires extensive computational analysis. 
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Accurate and reliable quantification of miRNAs still remains a 
challenging task. Only a small fraction of the mass in total 
RNA samples (~0.01%)14 represents miRNA content and their 
expression levels can vary by as much as four orders of mag-
nitude, requiring techniques with a wide dynamic range. An-
other issue is the sequence similarity among some miRNA-
family members whose presence may distort the final analysis. 
Taken together all these difficulties, it is clear that there is an 
unmet need for rapid and highly sensitive and selective miR-
NA analysis methods that can effectively profile miRNAs in 
minimal amounts of sample. Several biosensor methods have 
been proposed to date as alternative approaches to detect 
miRNAs for disease diagnosis.14, 20 In particular, optical bio-
sensors are promising tools for the detection of miRNAs due 
to the advantages of preamplification-free analysis, limit of 
detection (LOD) at the femtomolar-attomolar (fM-aM) range, 
short time-to-results, multiplexing capability, and minimal 
sample preparation requirement, thus avoiding the introduc-
tion of measurement bias.  
Different approaches based on optical biosensors for label-free 
detection of miRNAs have been proposed. In order to achieve 
wider dynamic ranges and appropriate sensitivity levels, these 
approaches have made use of amplification steps by employ-
ing specific antibodies for DNA/miRNA hybrids21, 22 or gold 
nanoparticles15, 23 to enhance the sensor signal. They have 
shown fast time to result and have achieved LODs in the low 
pM and fM concentrations. A Localized Surface Plasmon 
Resonance (LSPR) sensor using highly sensitive nanostruc-
tures (gold nanoprisms) achieved an ultra-sensitive detection 
of miRNAs at a LOD 91 aM in complex media avoiding the 
need for an amplification step.24 However, this biosensor 
lacked real-time evaluation and required very long incubation 
times. Therefore, despite the advances achieved, all the above 
techniques have not shown a rapid detection of miRNAs with 
high sensitivities in a single reaction. In addition, most of them 
do not have multiplexing capabilities, which is a main re-
quirement for routine clinical applications due to the limited 
sample obtained from patients, the low abundance of miRNAs, 
and the complexity of the sample composition. 
Integrated interferometric biosensors constitute highly sensi-
tive analytical platforms with a miniaturized size compatible 
with complementary metal-oxide-semiconductor (CMOS) 
fabrication processes, emerging as promising candidates for 
Lab-on-Chip devices. They represent an ideal platform for the 
direct and multiple miRNA detection during the analysis of 
complex samples avoiding pre- and post-amplification steps 
and with minimal sample input, thus saving time and re-
sources. Recently, a novel integrated optical biosensor based 
on a slot waveguide Mach-Zehnder interferometer (MZI) 
configuration has been developed for miRNA detection.25 It 
showed a rapid, accurate, and multiplexed detection of miR-
NAs in human urine samples in a single reaction, but its sensi-
tivity levels (≤1nM) were too far from the required ones.  
We present a highly sensitive nanophotonic biosensor for 
miRNA detection based on bimodal nanowaveguide interfer-
ometers (BiMW biosensor). The BiMW biosensor has been 
previously developed in our Group26 and is fabricated with 
advanced silicon nanotechnology. It consists of a single chan-
nel waveguide interferometer whose mechanism relies on the 
interference of two waveguide modes of the same polarization 
avoiding light beam splitting and recombination. This novel 
interferometric arrangement has improved tolerance to fabrica-
tion variation and a smaller footprint, opening the possibility 
to fabricate more devices in the same area, with a consequent 
increased of the reproducibility and reliability of the sensing 
evaluations. In particular, we targeted miR-181a that repre-
sents a potential biomarker for cancer prediction due to its 
implication in the metabolic shift of cancerous cells.27 Over-
expression of miR-181a has been demonstrated in colon27 and 
breast cancer,28 hepatocellular carcinoma,29 human gastric30 
and bladder cancer tissues.31, 32 The high sensitivity of the 
BiMW nanobiosensor allows for the rapid detection (≤ 30 
min) of miRNAs at a concentration as low as 23 aM, employ-
ing low amounts of sample input with no need for miRNA 
amplification. We also screened the levels of native endoge-
nous miRNAs of different bladder cancer patients and control 
urine samples and analyzed the alterative expression levels of 
miR-181a, demonstrating the applicability of the BiMW bio-
sensor for the routing clinical monitoring of miRNA levels for 
cancer prognosis, diagnosis and therapeutic follow-ups.  
 
EXPERIMENTAL SECTION 
Reagents, buffer solutions and miRNA sequences. The list 
of reagents, buffers and solvent used in this work and the 
design of miRNA sequences is provided in the Suplementary 
material. 
BiMW biosensor. The BiMW device is fabricated at wafer 
level using standard microelectronic technology in Clean 
Room facilities. An array of 16 interferometers of 30 mm 
length is integrated over a chip. A scheme of the BiMW bio-
sensor working principle is shown in Figure 1A. In brief, light 
from a polarized laser source (Helium-Neon, λ0= 660 nm) is 
first confined into a nanometric height rib waveguide (4 µm 
width x 1.5 nm height) designed to support a single transversal 
mode (150 nm thickness) (Section A). After some distance, 
this fundamental mode is coupled into a vertically bimodal 
section (300-350 nm thickness) through a step junction, i.e. a 
modal splitter (Section B).  At the step junction, due to the 
abrupt increase of the height of the waveguide core, it splits in 
two modes, the fundamental and the first order modes. These 
two modes propagate until the end of the device, resulting in 
an intensity distribution which depends on the phase differ-
ence between the two modes accumulated along the propaga-
tion length. A sensing window is opened along the bimodal 
section of the waveguide (Section C), where the evanescent 
field is in contact with the external medium and is sensitive to 
variations of the refractive index of the environment. Due to 
the different confinement factors of the propagating modes, 
the first order mode is the main responsible for the sensing of 
changes occurring on the waveguide surface while the funda-
mental mode can be considered as a virtual reference. The 
superposition of these two modes results in an intensity distri-
bution giving rise to an interferometric signal whose variations 
can be related to the amount of stimulus variation. On the 
sensor surface, when a biorecognition event occurs between a 
biorecognition layer and its concomitant target, the refractive 
index of the biosurface changes. This variation of the external 
refractive index affects the effective refractive index (N) of the 
propagating modes (TE00 for fundamental mode and TE10 for 
first order mode), producing a phase change (∆Φ): 
ΔΦ = 2π 	
 ( − ) 
where LSA is the length of the sensor area and λ is the working 
wavelength. The phase change produced is recorded by a two-
section photodetector at the end of the waveguide (Figure 1A, 
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Section D). Finally, a developed all-optical phase modulation 
method based on Fourier transform deconvolution33 is applied, 
modulating the interference signal to a real-time linear one, 
avoiding phase ambiguities (Figure 1B).  
Polymeric flow cell fabrication. The flow cell employed 
contained Polydimethylsiloxane (PDMS) channels and is 
fabricated by polymer casting using a methacrylate mold. 
Elastomer and curing agent are mixed in a ratio 10:1 and air 
bubbles originating from their mixing are removed by a vacu-
um degas process. The mixture is cured for 1 hour at 75ºC to 
ensure cross-linking of the polymer. After this thermal pro-
cess, the flow cell can be released from the methacrylate mold. 
The high hydrophobicity of the resulting PDMS channels is 
reduced by application of a Polyethylene glycol coating 
(PEG200, Sigma-Aldrich) after an ozone plasma treatment to 
expose functional groups on the polymer surface. Finally, 
PolyTetraFluoroEthylene (PTFE) tubes are inserted at each 
channel extremities and fixed with PDMS to avoid leakages or 
air insertion. The fluidic cell has four independent channels, 
with a volume of 15 µl each. Each fluidic channel addresses a 
group of four BiMW sensors on the fabricated chips. 
Si3N4-surface cleaning, activation and biofunctionalization. 
Si3N4 surfaces undergo an accurate cleaning prior to its use. 
First the chips are sonicated sequentially in acetone, ethanol 
and water, 2 min each. The cleaning process was finished by 
ultrasonication of the Si3N4 surfaces in a 1:1 meta-
nol/hydrochloric acid (MetOH/HCl) solution to remove other 
inorganic contamination. The chips are rinsed with milli-Q 
H2O and dried under a N2 stream. 
After chip cleaning, a layer of active hydroxyl group was 
generated on the surface by UV/O3 activation (BioForce Na-
nosciences, USA) and exposition to 15% nitric acid solution, 
revealing the oxide groups on the Si3N4 surface. Clean and 
hydroxyl-activated chips were immediately transferred in a 
1% v/v APTES solution prepared in water-free toluene under 
an argon atmosphere for 1 hour. 0.3 % v/v of N, N-
diisopropylethylamine (DIPEA) was employed to catalyze the 
hydrolysis reaction in the absence of water molecules. Finally, 
a curing step was performed at 110ºC for 1 hour. APTES-
modified surfaces were reacted with 20 mM PDITC in a solu-
tion of 10% anhydrous pyridine in N, N-dimethylformamide 
(DMF) for 1 hour in darkness. PDITC-activated APTES mon-
olayer were in-situ biofunctionalized by flowing a solution 
containing a mix of SH-T15-miR181a probes and SH-PEGs 
CO2H/NH2 at a molar ratio of 1:1 in 2 µM total concentration 
in 0.1M Na2CO3 buffer at pH 9.5 at a constant flow rate of 5 
µL/min.  
Detection conditions. miRNA target detection was performed 
by the injection of 250µL of the samples over the surface of 
the BiMW biosensor at a 15 µL/min rate, with a subsequent 
hybridization with their complementary DNA probes immobi-
lized on the sensor surface. Samples were dissolved in 5xSSC 
(0.75 M in NaCl, 0.075 M in sodium citrate) with several 
additives, such as 40% FA and 3M TMAC for enhancing 
specificity. Finally, target-probe interactions were disrupted by 
employing 35% FA freeing the probe for subsequent hybridi-
zation of the specific miRNA target (WARNING: Formamide 
is a known carcinogen. Carry out all steps involving pure 
formamide manipulation in a fume hood). Calibration curves 
were obtained by triplicate measurement of different dilutions 
from standards of known concentration. The mean and the 
standard deviation (SD) of each concentration were plotted 
versus the target concentration and a five-parameter model 
fitting was employed.  
Urine samples. For miR-181a detection study, the urine sam-
ples were kindly provided by Dr. M. Sánchez-Carbayo et al. 
from Centro de Investigación Lucio Lascaray (Vitoria-Gasteiz, 
Spain), Universidad del País Vasco. Samples were collected 
from bladder cancer patients and healthy donors and stored in 
a volume of 500 µL at -80ºC until their use. For the analysis, 
samples were unfrozen and diluted 1:10 in the highly stringent 
hybridization buffer. 
Data analysis. The data were analyzed using Origin 8.0 soft-
ware (OriginLab, Northampton, MA). The experimental detec-
tion limit (LOD) was defined as the target concentration giv-
ing a ∆Φ (rad) in the hybridization signal at least three times 
higher than that of the standard deviation of the miRNA con-
trol signal. 
 
 
 
 
Figure 1. Photograph and working principle of a BiMW sensor chip. (A) Working principle of the BiMW interferometer: TE-polarized light is 
coupled in the waveguide (Section A) and propagates in its fundamental mode; it splits in two modes after the step junction (Section B) which 
propagate along the waveguide and generate an interferometric signal which will vary depending on whether the miR-181a hybridize or not with its 
specific probe at the biosensing area (Section C). (B) Optical phase modulation of the interferometric interferences. (C) Biofunctionalization strat-
egy on the Si3N4 surface achieved by the generation of an APTES monolayer, activation of the amine groups through PDITC crosslinker and bio-
functionalization with SH-T15-miR-181a probes via thiocarbamate bonds. 
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Table 1. Sequences for miR-181a probe and miRNAs synthetic 
targets employed for the optimization of the selective quantification 
of miR-181a. 
 
RESULTS AND DISCUSSION 
BiMW biosensor biofunctionalization. For a proper biofunc-
tionalization, a suitable anchorage of the probe must be per-
formed on the sensing area. For that, the BiMW sensor surface 
(Si3N4) was chemically modified with 3-aminopropyltriethoxy 
(APTES) silane, one of the most widespread used silanes in 
biofunctionalization processes since it generates a homogene-
ous monolayer under controlled conditions. This silane pro-
vides silicon surfaces with end amine groups34, 35 that can 
incorporate different crosslinkers for the biofunctionalization 
of different biomolecules with specific chemical groups. For 
the APTES-monolayer activation, we employed 1,4-
phenylenediisothiocyanate (PDITC) which is a small homo-
bifunctional crosslinker commonly used in bioconjugation 
chemistry.36 It has two isothiocyanate (R-NCS) groups at both 
ends, which are stable in solution and reactive to primary 
amine groups through thiourea bonds. On the other hand, R-
NCS group also reacts with thiol groups, forming thiocarba-
mate bonds in a fast reaction.37 The reactive capabilities and 
the easy management in solution of PDITC make this cross-
linker very suitable for its employment for APTES-monolayer 
activation by thiourea bond formation. For miR-181a selective 
detection, we designed a single-stranded DNA probe contain-
ing the complementary sequence of miR-181a (Table 1). The 
DNA probe also had a sequence of 15 thymines (polyT15), for 
vertical spacing, aiding the probe accessibility to the target,38 
and a functional thiol (-SH) group at the 5’ end. The end thiol 
group serves as a reactive site for the coupling of the probes to 
the free R-NCS groups of the PDITC-activated APTES mono-
layer via thiocarbamate bonds (Figure 1C).  
For DNA probe immobilization, the chip was placed in the 
experimental set-up and encapsulated with the fluidic cell. We 
injected a mixed solution of SH-T15-miR-181a probes and SH-
PEG CO2H /NH2 in the flow delivery system and flowed it 
over the sensor surface at a 5 µL/min constant rate. The PEG 
compounds have been demonstrated to serve as both, a surface 
backfiller, preventing from non-specific adsorptions, and a 
horizontal spacer for SH-DNA probes, aiding the control of 
the probe density.39 Figure 2A shows a scheme of the func-
tionalization process. The covalent binding of the thiolated 
molecules to the PDITC-activated surface was monitored in 
real-time by the analysis of the modulated interferometric 
signals of the BiMW sensor (Figure 2B). As can be appreciat-
ed, the anchorage of the probes onto the surface gave rise to a 
positive shift in the phase change (∆Φ (rad) = 62.1), indicating 
that the DNA probe coupling through thiocarbamate bonds 
took place at the sensor surface. 
Selective detection of miRNA-181a at attomolar level with 
the BiMW biosensor. To demonstrate the proper performance 
of the miRNA BiMW biosensor, we tested the selective detec-
tion of miR-181a. MiR-181a belongs to the miR-181 family 
which includes four highly conserved mature miRNAs (miR-
181a, b, c, and d) derived independently from six precursors 
located on three different chromosomes. The four members of 
the human miR-181 family contain similar sequences that 
differ only in one to four nucleotides (Table 1). Although all 
members preserve the same seed sequence, they have in many 
cases distinct gene targets as in the case of leukemia inhibitory 
factor, which is targeted by miR-181d but not by miR181a.40 
In addition, while miR-181a and miR-181c encode almost 
identical mature miRNAs, the strength and functional specific-
ity of these miRNAs may be modulated through their pre-
miRNA loop nucleotides and/or by additional post-
transcriptional processes.41, 42 This highlights the non-
redundant role of miR-181 family members and adds a poten-
tial new level of complexity for their role in cancer develop-
ment, which makes mandatory the specific differentiation of 
these family members in order to establish a reliable diagnos-
tic tool.  
 
 
Figure 2. Biofunctionalization of the BiMW sensor surface. (A) 
Scheme of the functionalization process performed for miRNA detec-
tion. (B) Real-time biMW response to the immobilization of the SH-
T15-miR181a probe and SH-PEG CO2H/NH2 mix over a PDITC-
activated APTES monolayer (step 4). The sensogram shows the 
interaction of the injected solution with the PDITC-activated APTES 
monolayer (SH-T15-miR-181a on) reaching the equilibrium (SH-T15-
miR-181a off) and giving rise to a notable increment of the phase-
modulated signal. 
 
Name Sequence 
miR-181a probe 5’-(SH)-(PolyT15)-ACTCACCGACAGCGT 3’ 
 
Pre-miR-181a  5’GUGGUUGCUUCAGUGAACAUUCAACGCU
GUCGGUGAGUUUGGGAUUAAAGUGAAAACCA
UCGACCGUUGAUUGUACCCUCCAGCUAACCA
UCC 3’ 
miR-181a 5’AACAUUCAACGCUGUCGGUGAGU 3’ 
miR-181b 5’AACAUUCAUUGCUGUCGGUGGGU 3’ 
miR-181c 5’AACAUUCAAC - CUGUCGGUGAGU 3’ 
miR-181d 5’AACAUUCAUUGUUGUCGGUGGGU 3’ 
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Furthermore, the methodology should have a high capability 
to discriminate the pre- and mature miRNA to elucidate miR-
NA function and to facilitate the translation of miRNA detec-
tion method into the clinical practice.  
To guarantee the specific detection of miR-181a and its ho-
mologous discrimination, we employed a hybridization buffer 
containing certain additives as formamide (FA) and tetrame-
thylamonium chloride (TMAC) in 5x SSC buffer solution (i.e. 
5x SSC/ FA40%/ 3M TMAC). These additives provide highly 
stringent conditions in order to prevent from non-desirable 
cross-hybridizations from the homologous miRNAs. Concrete-
ly, a high percentage of FA has been demonstrated to have a 
remarkably positive effect in the hybridization efficiency and 
discrimination of homologous sequences.43 TMAC has been 
reported to be an isostabilizing agent, altering the melting 
temperature and making the hybridization solely dependent on 
oligonucleotide length independently of their GC content.44, 45, 
46  
We studied the effect of such compounds individually and 
their combinatorial effect employing a Surface Plasmon Reso-
nance (SPR) biosensor since it is a well-established technique 
for label-free analyses (see Supporting Information). We 
demonstrated their discriminating effect over non-fully com-
plementary sequences and we observed a notorious enhance-
ment in the hybridization efficiency on the fully complemen-
tary sequences (Figure S2 and S3). Therefore, we tested the 
selectivity in the BiMW biosensor under these conditions by 
monitoring the biosensor response after the injection of the 
different homologous as well as the pre-miR-181a at a 100 pM 
concentration. As can be appreciated in the sensogram depict-
ed in Figure 3A, all non-specific sequences returned to the 
baseline after the replacement with the running buffer while 
miR-181a produced a clearly appreciable positive shift in the 
biosensor response (∆Φ (rad) = 2.8), confirming the selective 
detection of miR-181a and the total discrimination of the 
homologous sequences. 
Once we demonstrated the selectivity of the BiMW biosensor 
for miR-181a, we assessed its sensitivity. For that purpose, we 
performed a calibration curve for the direct analysis of miR-
181a in the highly stringent buffer conditions previously em-
ployed. We injected in the BiMW biosensor different concen-
trations of miR-181a from standard solutions, covering a wide 
range of concentrations, from 10 aM to 10 nM. For all the 
concentration tested, an increase in the signal in a concentra-
tion dependent manner was detected by the formation of dou-
ble-stranded DNA/miRNA heteroduplexes. The BiMW re-
sponse to the range of concentrations of the synthetic miRNAs 
was fitted to a five-parameter logistic function.47 As can be 
observed in Figure 3C, the BiMW device was able to clearly 
detect a wide range of miR-181a concentrations in the aM-pM 
range, achieving an ultra-low LoD of only 23 aM. The theoret-
ical limit of quantification (LOQ) calculated was 79 aM, 
which is in close agreement with the minimum concentration 
measured (100 aM). The curve covered a wide range of con-
centrations reaching its saturating signal at concentrations 
equal or higher to 10 pM. Concentration-response calibration 
curve showed a good fitting (R2 = 0.99) in the range of con-
centrations evaluated, which is advantageous for the real-time 
detection of miRNAs having wide-ranged expression profiles 
in the different stages during cancer development. The ob-
tained LOD was 1000 million times more sensitive than the 
one achieved with the previously published multiplexed MZI 
biosensor25 and more than four times better than the one ob-
tained for the miRNA LSPR-based detection (92 aM).24 In 
addition, our biosensor was capable to clearly monitor in real-
time miR-181a interactions at concentrations as low as 100 
aM directly without pre- or post- amplification processes 
(Figure 3B).  
 
MiRNA-181 analysis in urine samples. In order to demon-
strate the capabilities of our biosensor for real analysis, the 
next step was the evaluation of human samples. As previously 
described, miR-181a is involved in the development and pro-
liferation of various cancers and its overexpression has been 
demonstrated in both circulating biofluids and tumor tissues. 
Among the different cancer types, we selected bladder cancer 
for a preliminary evaluation of the biosensor strategy as a 
rapid and non-invasive diagnostic tool. Bladder cancer is the 
fifth most common malignancy occurring worldwide and a 
major cause of cancer morbidity and mortality.48 Current 
standard methods used to detect and monitor bladder cancer 
are invasive or have low sensitivity. Cytoscopy and cytology 
are the standard methods normally employed in bladder cancer 
diagnosis. The former one has a high sensitivity, but constitute 
an invasive technique, while the latter one is non-invasive but 
lacks sensitivity, especially for low-grade disease.49 These 
limitations have prompted the search for more reliable non-
invasive tools. For example, an accurate urinary test to detect 
bladder cancer would improve patient quality of life and out-
come. Currently, less-invasive methods based in various urine 
tests have been commercialized but even though most of them 
are more sensitive, urine cytology continues to be more specif-
ic. Using microRNA profiling in urine samples to develop a 
non-invasive test for bladder cancer is of high interest. In 
addition, their stability in human urine supports their bi-
omarker potential.50 MiRNA screening in urine has demon-
strated detectable miRNA species and differences in the miR-
NA spectra suggests the possibility that changes in the miRNA 
composition in urine can be used to identify physiopathologi-
cal conditions.50, 51  
We attempted the analysis of miR-181a in real human urine 
samples. To ensure the anti-fouling properties of the receptor 
monolayer, miR-181a spike-in urine samples from healthy 
individual were first tested over the BiMW interferometer 
modified only with a 100% SH-PEG CO2H /NH2 at a 1 µM 
concentration. Such monolayer would help to assess possible 
nonspecific adsorptions of urine matrix components, which 
may lead to false positive. We also analyzed the response of 
the monolayer containing the complementary probe for miR-
181a.  
The samples were diluted 1:1 in the highly selective hybridiza-
tion buffer and spiked-in with miR-181a before their injection 
in the flow delivery system. Variations in BiMW response 
were monitored in real time. As can be appreciated in Figure 
4A, the control receptor monolayer did not show any incre-
ment in the sensor signal at the equilibrium after the injection 
of the urine sample. On the other hand, an increment of ∆Φ 
(πrad) = 1.69 was appreciated in the monolayer modified with 
the specific probe for miR-181a. 
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Figure 3. Detection of miR-181a by the BiMW biosensor biofunctionalized with a mix of SH-T15-miR181a probes and SH-PEGs CO2H/NH2 at a 
molar ratio of 1:1 in 2 µM total concentration. (A) BiMW sensogram showing the specific detection of miR-181a (blue line) and discrimination of 
pre-miR-181a (black) and its homologous miRNAs 181b (purple), 181c (green) and 181d (yellow) at 100 pM concentration. (B) Sensograms 
obtained for the lowest concentration evaluated with the BiMW biosensor (0.1, 0.5 and 1 fM). (C) Calibration curve obtained for different concen-
trations of miR-181a standard solutions (10 aM- 10 nM) in semi-log scale. Solid blue line corresponds to the exponential fit of the calibration curve 
(R2 = 0.99). All data show mean ± standard deviation (SD) of triplicate measurements. 
These results confirmed that the methodology was highly 
specific toward the target miRNA and manifested that, in case 
we obtained a positive signal in the BiMW biosensor, it would 
presumably come from the specific hybridization of miR-181a 
to the probe at the biosensor surface. 
To study the different expression of miR-181a in bladder 
cancer, we analyzed four urine clinical samples from both 
healthy donors (S1 and S2) and bladder cancer patients (S3 
and S4). Urine samples were diluted 1:10 with the hybridiza-
tion buffer to avoid possible saturating signals and to perform 
a more accurate analysis, and flowed over the biosensor sur-
face. The signals were monitored in real time and converted 
into the corresponding concentrations using the calibration 
curve derived for miR-181a and corrected by the applied dilu-
tion factor (Figure 4B). Both healthy donors showed similar 
miR-181a expression (0.63 and 0.58 pM for S1 and S2, re-
spectively).  BiMW biosensor results indicated that miR-181a 
levels were higher in bladder cancer patients (15.1 and 18.3 
pM for S3 and S4, respectively) compared to healthy control 
subjects, showing a 28 fold-change. These results indicated a 
clearly different expression of miR-181a between healthy 
individuals and bladder cancer patients, which suggested a 
possible direct implication of such miRNA in the onset of this 
malignancy. The miRNA can be quantified with high accuracy 
using the BiMW biosensor in a wide range of concentrations 
without the need of any modification, amplification, or label-
ing.  
 
 
CONCLUSIONS 
We have demonstrated the efficiency and ultra-sensitivity of 
the BiMW biosensor for the quantitative detection of cancer-
associated miRNAs directly in human fluids. Concretely, we 
have applied it for the detection of miR-181a, a promising 
biomarker for cancer diagnosis due to its implication in the 
metabolism shift in cancerous cells. This miRNA BiMW 
biosensor, with a LOD of 23 aM, represents the most sensitive 
approach for miRNA detection so far described in a direct 
detection and quantification of miRNA levels without amplifi-
cation or labeling steps.   Discrimination between the different 
homologous and pre-miRNA of miR-181a has been achieved 
in a wide dynamic range of concentrations (aM-pM). Moreo-
ver, the BiMW analysis of human urine samples showed over-
expression of miR-181a in bladder cancer patients as com-
pared to control individuals, suggesting for the first time the 
direct implication of this miRNA in the outcome of this specif-
ic cancer.  Further studies should be performed to confirm the 
implication of miR-181a in bladder cancer through metabolic 
shift and to establish a proper cut-off for the early determina-
tion of cancer onset. 
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Figure 4. Analysis of miR-181a in human urine samples in the BiMW biosensor biofunctionalized with a mix of SH-T15-miR181a probes and SH-
PEGs CO2H/NH2 at a molar ratio of 1:1 in 2 µM total concentration. (A) Sensograms showing the signals of spiked-in urine samples when employ-
ing the anti-fouling monolayer with the specific miR-181a probe (green line) and a control anti-fouling monolayer (black line). (B) Concentrations 
of miR-181a in urine samples from healthy donors (0.6 pM) and bladder cancer patients (16.7 pM) obtained by interpolation of the BiMW biosen-
sor signal in the calibration curve (Figure 3C). 
 
Overall, the proposed biosensor is the first methodology re-
ported in BiMW for nucleic acid detection with clinical pur-
poses and constitutes an extraordinary opportunity for the 
development of multiplexed Lab-on-a-Chip platforms that 
provide simultaneous detection of specific miRNA panels in 
very low amounts of human fluids with ultra-high sensitivity. 
The implementation in Point-of-Care systems may drastically 
improve not only cancer diagnosis and prognosis, but also may 
increase treatment and curation probabilities.  
ASSOCIATED CONTENT  
Supporting Information 
The Supporting Information is available free of charge on the 
ACS Publications website. 
 
Additional text describing reagents, solvents and the 
sources and software employed for the design of the 
miRNA sequences, as well as, the Surface Plasmon 
Resonance biosensor and the optimization performed 
for miR-181a specific detection (PDF). 
 
AUTHOR INFORMATION 
Corresponding Author 
*L. M. Lechuga: laura.lechuga@cin2.es. Tel.: + 34 93 737 4620 
Author Contributions 
The manuscript was written through contributions of all authors. / 
All authors have given approval to the final version of the manu-
script.  
Funding Sources 
This work was financially supported by EPISENS project of the 
Spanish Ministry of Science and Innovation (TEC2012-3428). 
The nanoB2A is a consolidated research group (Grup de Recerca) 
of the Generalitat de Catalunya and has support from 
the Departament d’Universitats, Recerca i Societat de la Infor-
mació de la Generalitat de Catalunya (2014 SGR 624). 
 
ACKNOWLEDGMENT  
ICN2 acknowledges support of the Spanish MINECO through 
the Severo Ochoa Centers of Excellence Program under Grant 
SEV-2013-0295. We thank to Dr. M. Sánchez-Carbayo et al. from 
Centro de Investigación Lucio Lascaray (Vitoria-Gasteiz, Spain), 
Universidad del País Vasco, for supplying urine samples. 
REFERENCES 
1. Lim, L. P.; Lau, N. C.; Garrett-Engele, P.; Grimson, A.; 
Schelter, J. M.; Castle, J.; Bartel, D. P.; Linsley, P. S.; Johnson, J. M., 
Microarray analysis shows that some microRNAs downregulate large 
numbers of target mRNAs. Nature 2005, 433 (7027), 769-773. 
2. He, L.; Hannon, G. J., MicroRNAs: small RNAs with a big 
role in gene regulation. Nature Reviews Genetics 2004, 5 (7), 522-531. 
3. Iorio, M. V.; Croce, C. M., MicroRNA dysregulation in cancer: 
diagnostics, monitoring and therapeutics. A comprehensive review. 
EMBO molecular medicine 2012, 4 (3), 143-159. 
4. Lu, J.; Getz, G.; Miska, E. A.; Alvarez-Saavedra, E.; Lamb, J.; 
Peck, D.; Sweet-Cordero, A.; Ebert, B. L.; Mak, R. H.; Ferrando, A. A., 
MicroRNA expression profiles classify human cancers. Nature 2005, 435 
(7043), 834-838. 
5. Rosenfeld, N.; Aharonov, R.; Meiri, E.; Rosenwald, S.; 
Spector, Y.; Zepeniuk, M.; Benjamin, H.; Shabes, N.; Tabak, S.; Levy, A., 
MicroRNAs accurately identify cancer tissue origin. Nature biotechnology 
2008, 26 (4), 462-469. 
6. Schwarzenbach, H.; Hoon, D. S.; Pantel, K., Cell-free nucleic 
acids as biomarkers in cancer patients. Nature Reviews Cancer 2011, 11 
(6), 426-437. 
7. Taylor, D. D.; Gercel-Taylor, C., MicroRNA signatures of 
tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. 
Gynecologic oncology 2008, 110 (1), 13-21. 
8. Hanke, M.; Hoefig, K.; Merz, H.; Feller, A. C.; Kausch, I.; 
Jocham, D.; Warnecke, J. M.; Sczakiel, G. In A robust methodology to 
study urine microRNA as tumor marker: microRNA-126 and microRNA-
182 are related to urinary bladder cancer, Urologic Oncology: Seminars 
and Original Investigations, Elsevier: 2010; pp 655-661. 
9. Michael, A.; Bajracharya, S. D.; Yuen, P. S.; Zhou, H.; Star, R. 
A.; Illei, G. G.; Alevizos, I., Exosomes from human saliva as a source of 
microRNA biomarkers. Oral diseases 2010, 16 (1), 34-38. 
10. Xie, Y.; Todd, N. W.; Liu, Z.; Zhan, M.; Fang, H.; Peng, H.; 
Alattar, M.; Deepak, J.; Stass, S. A.; Jiang, F., Altered miRNA expression 
in sputum for diagnosis of non-small cell lung cancer. Lung cancer 2010, 
67 (2), 170-176. 
11. Heneghan, H. M.; Miller, N.; Lowery, A. J.; Sweeney, K. J.; 
Newell, J.; Kerin, M. J., Circulating microRNAs as novel minimally 
Page 7 of 9
ACS Paragon Plus Environment
ACS Sensors
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 8
invasive biomarkers for breast cancer. Annals of surgery 2010, 251 (3), 
499-505. 
12. Bader, A. G.; Lammers, P., The therapeutic potential of 
microRNAs. Innovations in Pharmaceutical Technology 2011, 52-55. 
13. Ling, H.; Fabbri, M.; Calin, G. A., MicroRNAs and other non-
coding RNAs as targets for anticancer drug development. Nature reviews 
Drug discovery 2013, 12 (11), 847-865. 
14. Dong, H.; Lei, J.; Ding, L.; Wen, Y.; Ju, H.; Zhang, X., 
MicroRNA: function, detection, and bioanalysis. Chemical reviews 2013, 
113 (8), 6207-6233. 
15. Vaisocherová, H.; Šípová, H.; Víšová, I.; Bocková, M.; 
Špringer, T.; Ermini, M. L.; Song, X.; Krejčík, Z.; Chrastinová, L.; Pastva, 
O., Rapid and sensitive detection of multiple microRNAs in cell lysate by 
low-fouling surface plasmon resonance biosensor. Biosensors and 
Bioelectronics 2015, 70, 226-231. 
16. Benes, V.; Castoldi, M., Expression profiling of microRNA 
using real-time quantitative PCR, how to use it and what is available. 
Methods 2010, 50 (4), 244-249. 
17. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; 
Lendeckel, W.; Tuschl, T., Identification of tissue-specific microRNAs 
from mouse. Current Biology 2002, 12 (9), 735-739. 
18. Thomson, J. M.; Parker, J.; Perou, C. M.; Hammond, S. M., A 
custom microarray platform for analysis of microRNA gene expression. 
Nature methods 2004, 1 (1), 47-53. 
19. Eminaga, S.; Christodoulou, D. C.; Vigneault, F.; Church, G. 
M.; Seidman, J. G., Quantification of microRNA Expression with Next‐
Generation Sequencing. Current Protocols in Molecular Biology 2013, 
4.17. 1-4.17. 14. 
20. Hamidi-Asl, E.; Palchetti, I.; Hasheminejad, E.; Mascini, M., A 
review on the electrochemical biosensors for determination of 
microRNAs. Talanta 2013, 115, 74-83. 
21. Sipova, H.; Zhang, S.; Dudley, A. M.; Galas, D.; Wang, K.; 
Homola, J., Surface Plasmon Resonance Biosensor for Rapid Label-Free 
Detection of Microribonucleic Acid at Subfemtomole Level Analytical 
Chemistry Article ASAP 2010, 82 (24), 10110-10115. 
22. Qavi, A. J.; Kindt, J. T.; Gleeson, M. A.; Bailey, R. C., Anti-
DNA: RNA antibodies and silicon photonic microring resonators: 
increased sensitivity for multiplexed microRNA detection. Analytical 
chemistry 2011, 83 (15), 5949-5956. 
23. Wang, Q.; Li, Q.; Yang, X.; Wang, K.; Du, S.; Zhang, H.; Nie, 
Y., Graphene oxide–gold nanoparticles hybrids-based surface plasmon 
resonance for sensitive detection of microRNA. Biosensors and 
Bioelectronics 2016, 77, 1001-1007. 
24. Joshi, G. K.; Deitz-McElyea, S.; Liyanage, T.; Lawrence, K.; 
Mali, S.; Sardar, R.; Korc, M., Label-Free Nanoplasmonic-Based Short 
Noncoding RNA Sensing at Attomolar Concentrations Allows for 
Quantitative and Highly Specific Assay of MicroRNA-10b in Biological 
Fluids and Circulating Exosomes. ACS nano 2015, 9 (11), 11075-11089. 
25. Liu, Q.; Shin, Y.; Kee, J. S.; Kim, K. W.; Rafei, S. R. M.; 
Perera, A. P.; Tu, X.; Lo, G.-Q.; Ricci, E.; Colombel, M., Mach–Zehnder 
interferometer (MZI) point-of-care system for rapid multiplexed detection 
of microRNAs in human urine specimens. Biosensors and Bioelectronics 
2015, 71, 365-372. 
26. Zinoviev, K.; Gonzalez Guerrero, A.; Dominguez, C.; 
Lechuga, L., Integrated Bimodal Waveguide Interferometric Biosensor for 
Label-Free Analysis. Journal of Lightwave Technology 2011, 29 (13), 
1926-1930. 
27. Wei, Z.; Cui, L.; Mei, Z.; Liu, M.; Zhang, D., miR-181a 
mediates metabolic shift in colon cancer cells via the PTEN/AKT 
pathway. FEBS letters 2014, 588 (9), 1773-1779. 
28. Jiao, X.; Zhao, L.; Ma, M.; Bai, X.; He, M.; Yan, Y.; Wang, 
Y.; Chen, Q.; Zhao, X.; Zhou, M., MiR-181a enhances drug sensitivity in 
mitoxantone-resistant breast cancer cells by targeting breast cancer 
resistance protein (BCRP/ABCG2). Breast cancer research and treatment 
2013, 139 (3), 717-730. 
29. Ji, J.; Yamashita, T.; Wang, X. W., Wnt/beta-catenin signaling 
activates microRNA-181 expression in hepatocellular carcinoma. Cell 
Biosci 2011, 1 (4), 10.1186/2045-3701-1-4. 
30. Zhang, X.; Nie, Y.; Du, Y.; Cao, J.; Shen, B.; Li, Y., 
MicroRNA-181a promotes gastric cancer by negatively regulating tumor 
suppressor KLF6. Tumor Biology 2012, 33 (5), 1589-1597. 
31. Puzio-Kuter, A. M.; Castillo-Martin, M.; Kinkade, C. W.; 
Wang, X.; Shen, T. H.; Matos, T.; Shen, M. M.; Cordon-Cardo, C.; Abate-
Shen, C., Inactivation of p53 and Pten promotes invasive bladder cancer. 
Genes & development 2009, 23 (6), 675-680. 
32. Song, T.; Xia, W.; Shao, N.; Zhang, X.; Wang, C.; Wu, Y.; 
Dong, J.; Cai, W.; Li, H., Differential miRNA expression profiles in 
bladder urothelial carcinomas. Asian Pac J Cancer Prev 2010, 11 (4), 
905-911. 
33. Dante, S.; Duval, D.; Sepúlveda, B.; González-Guerrero, A. B.; 
Sendra, J. R.; Lechuga, L. M., All-optical phase modulation for integrated 
interferometric biosensors. Optics express 2012, 20 (7), 7195-7205. 
34. Diao, J.; Ren, D.; Engstrom, J. R.; Lee, K. H., A surface 
modification strategy on silicon nitride for developing biosensors. 
Analytical biochemistry 2005, 343 (2), 322-328. 
35. Fernandez, R. E.; Bhattacharya, E.; Chadha, A., Covalent 
immobilization of Pseudomonas cepacia lipase on semiconducting 
materials. Applied Surface Science 2008, 254 (15), 4512-4519. 
36. Manning, M.; Harvey, S.; Galvin, P.; Redmond, G., A versatile 
multi-platform biochip surface attachment chemistry. Materials Science 
and Engineering: C 2003, 23 (3), 347-351. 
37. Gokmen, M. T.; Brassinne, J.; Prasath, R. A.; Du Prez, F. E., 
Revealing the nature of thio-click reactions on the solid phase. Chemical 
Communications 2011, 47 (16), 4652-4654. 
38. Steel, A. B.; Levicky, R. L.; Herne, T. M.; Tarlov, M. J., 
Immobilization of nucleic acids at solid surfaces: effect of oligonucleotide 
length on layer assembly. Biophysical journal 2000, 79 (2), 975-981. 
39. Joshi, G. K.; Deitz-McElyea, S.; Johnson, M.; Mali, S.; Korc, 
M.; Sardar, R., Highly specific plasmonic biosensors for ultrasensitive 
microRNA detection in plasma from pancreatic cancer patients. Nano 
letters 2014, 14 (12), 6955-6963. 
40. Belkaya, S.; Silge, R. L.; Hoover, A. R.; Medeiros, J. J.; 
Eitson, J. L.; Becker, A. M.; de la Morena, M. T.; Bassel-Duby, R. S.; van 
Oers, N., Dynamic modulation of thymic microRNAs in response to 
stress. PloS one 2011, 6 (11), e27580. 
41. Kuchen, S.; Resch, W.; Yamane, A.; Kuo, N.; Li, Z.; 
Chakraborty, T.; Wei, L.; Laurence, A.; Yasuda, T.; Peng, S., Regulation 
of microRNA expression and abundance during lymphopoiesis. Immunity 
2010, 32 (6), 828-839. 
42. Liu, G.; Min, H.; Yue, S.; Chen, C.-Z., Pre-miRNA loop 
nucleotides control the distinct activities of mir-181a-1 and mir-181c in 
early T cell development. PloS one 2008, 3 (10), e3592-e3592. 
43. Huertas, C. S.; Carrascosa, L.; Bonnal, S.; Valcárcel, J.; 
Lechuga, L., Quantitative evaluation of alternatively spliced mRNA 
isoforms by label-free real-time plasmonic sensing. Biosensors and 
Bioelectronics 2016, 78, 118-125. 
44. Duby, A.; Jacobs, K. A.; Celeste, A., Using synthetic 
oligonucleotides as probes. Current Protocols in Molecular Biology 2001, 
6.4. 1-6.4. 10. 
45. Napolitano, N. M.; Rohlfs, E. M.; Heim, R. A., Simultaneous 
Detection of Multiple Point Mutations Using Allele‐Specific 
Oligonucleotides. Current Protocols in Human Genetics 2004, 9.4. 1-9.4. 
10. 
46. Schwinefus, J. J.; Kuprian, M. J.; Lamppa, J. W.; Merker, W. 
E.; Dorn, K. N.; Muth, G. W., Human telomerase RNA pseudoknot and 
hairpin thermal stability with glycine betaine and urea: Preferential 
interactions with RNA secondary and tertiary structures. Biochemistry 
2007, 46 (31), 9068-9079. 
47. Giraldo, J.; Vivas, N. M.; Vila, E.; Badia, A., Assessing the (a) 
symmetry of concentration-effect curves: empirical versus mechanistic 
models. Pharmacology & therapeutics 2002, 95 (1), 21-45. 
48. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; 
Ghafoor, A.; Feuer, E. J.; Thun, M. J., Cancer statistics, 2005. CA: a 
cancer journal for clinicians 2005, 55 (1), 10-30. 
49. Mengual, L.; Lozano, J. J.; Ingelmo‐Torres, M.; Gazquez, C.; 
Ribal, M. J.; Alcaraz, A., Using microRNA profiling in urine samples to 
develop a non‐invasive test for bladder cancer. International Journal of 
Cancer 2013, 133 (11), 2631-2641. 
50. Mall, C.; Rocke, D. M.; Durbin-Johnson, B.; Weiss, R. H., 
Stability of miRNA in human urine supports its biomarker potential. 
Biomarkers in medicine 2013, 7 (4), 623-631. 
51. Weber, J. A.; Baxter, D. H.; Zhang, S.; Huang, D. Y.; Huang, 
K. H.; Lee, M. J.; Galas, D. J.; Wang, K., The microRNA spectrum in 12 
body fluids. Clinical chemistry 2010, 56 (11), 1733-1741. 
 
 
 
Page 8 of 9
ACS Paragon Plus Environment
ACS Sensors
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
9
For TOC only 
 
Page 9 of 9
ACS Paragon Plus Environment
ACS Sensors
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
